Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
August 6, 2024
Earnings Call Speaker Segments
Zack Kubow
executiveThanks, operator, and good afternoon to all of you. We appreciate your attendance on this call covering Corvus Pharmaceuticals' business update and financial results for the second quarter of 2024. Here to walk through the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Jim Rosenbaum, Senior Vice President of Research; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Members of the executive team will begin with prepared remarks, after which we'll move to a question-and-answer session. I want to remind each of you that remarks made by management today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed today, along with other filings the company makes with the SEC periodically. The company assumes no obligation to publicly update or revise any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Leiv Lea. Leiv?
Leiv Lea
executiveThanks, Zack. I'll start by giving you a brief look at how our finances came out for the second quarter of 2024, and after that I'll hand things over to Richard so he can walk you through what's happening on the business side. When it comes to research and development expenses, we spent $4.1 million during the second quarter of 2024, versus $4.0 million across the equivalent stretch of 2023. Our net loss for the second quarter of 2024 came to $4.3 million, and that figure includes a non-cash loss of $0.6 million tied to Angel Pharmaceuticals, the partner we work with in China. Beyond that, we booked a non-cash gain of $1.8 million stemming from a shift in the fair value of Corvus' warrant liability in the second quarter of 2024, which relates to warrants sold as part of the financing we wrapped up in early May 2024. Set that against a net loss of $6.5 million for the matching period in 2023, a figure that carried a $1.3 million non-cash loss connected to Angel Pharmaceuticals. Total stock compensation expense landed at $0.8 million for the second quarter of 2024, compared with $0.5 million during the equivalent stretch of 2023. Coming into June 30, 2024, Corvus held cash, cash equivalents and marketable securities amounting to $47.3 million, whereas at December 31, 2023 that total stood at $27.1 million. Within that figure sits $30.3 million brought in through our May financing. Given our present plans, we expect the cash we have will fund us into the fourth quarter of 2025. One thing worth noting: the warrants sold in May carry an exercise price of $3.50 per warrant and lapsed on June 30, 2025. Should every one of those warrants get exercised, roughly $60 million in additional capital would come in. I'll pass the call along to Richard now, who will go over our clinical progress and get into more detail about our strategy and plans.
Richard Miller
executiveThanks, Leiv, and good afternoon to all of you. We appreciate you being with us today for this update on our business. At Corvus, we're leading the way in developing selective ITK inhibition as a novel treatment approach for a wide variety of immune-related conditions and cancer. Our next-generation ITK inhibitors, including soquelitinib, feature a distinctive mechanism of action that acts upstream to regulate critical T-cell signaling pathways. That mechanism holds particular importance for immune and inflammatory conditions, since it leads to modulation of several cytokines that serve as targets for therapies currently approved. The clinical evidence starting to emerge from our atopic dermatitis trial, along with our continuing preclinical efforts, supports the potential for soquelitinib and selective ITK inhibition across multiple large patient populations, encompassing conditions like atopic dermatitis, asthma, psoriasis, inflammatory bowel diseases, scleroderma and other fibrotic diseases. Our confidence keeps building in our ITK inhibitor program, which we think is now showing activity across a wide array of diseases extending beyond lymphoma and solid tumors. Advancing our lead ITK inhibitor, soquelitinib, remains our primary focus. The chance to address immune diseases through ITK inhibition is especially thrilling, thanks to its profile as an oral medication that is well tolerated, the clinical evidence emerging from our atopic dermatitis trial and our continuing preclinical efforts across a broad spectrum of immune diseases. On the cancer side, we're still on schedule to start enrolling patients in the third quarter for our planned registrational Phase III clinical trial of soquelitinib in those with relapsed peripheral T-cell lymphoma. And our belief in this trial keeps strengthening, as one more patient in our Phase I/Ib trial showed continued tumor regression and recently reached a complete response after having a partial response at the first follow-up; now I'll give you more specifics on our progress, beginning with the soquelitinib Phase I clinical trial involving patients who have moderate to severe atopic dermatitis. Several sites now have this clinical trial open, and we'll be adding more sites in light of our early encouraging experience. The trial is built to enroll 64 patients with moderate to severe atopic dermatitis whose disease has progressed on at least one prior therapy. This study is randomized, placebo-controlled and blinded to both patients and treating physicians. There will be 4 sequentially enrolled cohorts of 16 patients, with patients in each cohort randomized 3:1 to different dosing regimens of soquelitinib or placebo administered for 28 days. Safety and tolerability make up the primary endpoint, and efficacy is assessed through the clinically validated measurements of improvement in Eczema Area and Severity Index score, also known as EASI, and the Investigator Global Assessment. The first cohort, which uses the lowest soquelitinib dose of 100 milligrams BID, is enrolling at present, and a few patients have now finished the 28-day treatment regimen and follow-up. Although the patient and physician don't know the treatment assignment, the Corvus team isn't blinded to the trial results, and I can share that, though it's very early, we are seeing signs of clinical activity. Thus far, individuals who have received treatment are exhibiting meaningful gains in EASI scores by day 28, along with matching shifts in serum cytokine levels that align with how soquelitinib is believed to work. That's encouraging, particularly since this represents the cohort receiving the smallest dose; beyond that, we keep observing that the medication has a favorable tolerability profile, with no notable safety concerns brought to our attention so far. Interest remains strong in both the study and our innovative therapeutic. We expect to present interim results from the earliest cohorts during Q4. The initial preliminary findings from these first patients reveal key observations regarding serum cytokine levels that bolster the possibility of employing ITK inhibition against additional immune conditions. A number of these shifts mirror what we've observed in preclinical research involving other inflammatory conditions and imply that soquelitinib might prove efficacious against them; we look forward to presenting some of this research at the American College of Rheumatology conference in November. Evidence keeps accumulating that soquelitinib, along with selective ITK inhibition, might represent a valuable novel therapeutic strategy across a variety of immune and inflammatory conditions. Additional backing comes from recent research conducted in the laboratory of Professor Avery August at Cornell University. Dr. August ranks among the foremost immunologists and stands as a globally recognized authority on ITK. His team showed that ITK governs the destiny of inflammatory Th17 cells. Once soquelitinib blocks ITK, those developing Th17 cells transform or shift into Treg cells, which dampen inflammation. Administering soquelitinib in a mouse asthma model featuring allergic airway inflammation markedly lowered the proportion of Th17 cells within the lung, producing a rise in the ratio between T-regulatory cells and Th17 cells. Such findings affirm and broaden our grasp of how targeting specific ITK inhibition affects inflammation and hold relevance for numerous immune conditions. We're likewise continuing to push forward our second- and third-generation ITK inhibitors, which we're refining further for the treatment of immune and inflammatory conditions. Our preclinical efforts center on asthma, psoriasis, scleroderma, inflammatory bowel diseases and fibrotic diseases, alongside a multitude of other indications pinpointed for later work. Now, turning to an update on soquelitinib for peripheral T-cell lymphoma, or PTCL. Though we've stopped enrolling additional patients into our Phase I study, the data keeps developing as those receiving therapy finish their planned follow-up evaluations. In the latest data cutoff from July 15, we saw 1 more patient who displayed ongoing tumor regression, reaching a complete response following a partial response at the initial follow-up appointment. With this latest information, the objective response rate, or ORR, among Phase III eligible patients holds at 9 out of 23, or 39%, yet the count of complete responses has risen to 6, equating to a 26% complete response rate. Even though no head-to-head comparison was performed, the 26% complete response rate for soquelitinib exceeds by more than double what's observed with belinostat or pralatrexate, the conventional chemotherapies for PTCL that will serve as the comparators in our Phase III study. In the same way, for this group, the ORR, disease control rate, progression-free survival, and overall survival stack up well against what has been observed with belinostat or pralatrexate. Among our patients, median PFS — the primary endpoint of our Phase III trial — stands at 6.2 months. That is considerably superior to the figures reported for the standard agents: 1.6 months for belinostat and 3.5 months for pralatrexate. Our responses are impressively durable, with a number of the patients enrolled earlier continuing to hold their responses beyond 24 months. Enrollment of patients in our registrational Phase III clinical trial of soquelitinib in relapsed PTCL is scheduled to start in September of 2024. At present, no agents have full FDA approval for treating relapsed PTCL, and for soquelitinib in relapsed T-cell lymphoma, the FDA has extended both orphan drug designation and fast track designation. We recently obtained a pediatric waiver from FDA, meaning clinical trials in a pediatric population will not be required for this indication. We are collaborating with, or are in advanced discussions with, numerous leading centers across the United States, Australia, Canada and South Korea.
Richard Miller
executiveThis trial will randomize 150 patients to receive either soquelitinib or a standard-of-care option, and that standard of care will be pralatrexate or belinostat. Roughly 40 sites are expected to take part, with the great majority located in the United States. Among the participating study centers are MD Anderson, Memorial Sloan Kettering, City of Hope, Washington University, along with other prominent institutions. It's a pleasure to have these top academic centers on board, given their deep experience and expertise running clinical trials in T-cell lymphomas. Beyond our atopic dermatitis and PTCL studies, we're also putting together a soquelitinib trial in solid tumors, testing it as a single agent in relapsed renal cell cancer, which represents a novel way of approaching immunotherapy for this disease. In addition, we keep moving forward with our other clinical-stage development programs. We've been among the leaders in developing adenosine A2A receptor antagonism for cancer treatment with ciforadenant. That work includes our Phase Ib/II clinical trial, which is being run together with the Kidney Cancer Research Consortium. In this trial, cifo is being assessed as a possible first-line treatment for metastatic renal cell cancer, given in combination with ipilimumab and nivolumab. Enrollment is happening at MD Anderson, Vanderbilt, Duke and the University of Pennsylvania. Findings from this trial, along with supportive preclinical research that has been published, show the promise of pairing an anti-CTLA-4 antibody with ciforadenant to generate striking antitumor efficacy that outperforms what has been seen when cifo is combined with anti-PD-1s. In July, a new patent was granted in the United States covering our ciforadenant work, and matching applications abroad remain pending. According to the latest data analysis, dated May 31, 32 patients had enrolled, and the study keeps clearing our prespecified statistical hurdle for continuation, meaning it has achieved at least a 50% improvement in the deep response rate of 32%, which is the rate seen with the ipilimumab and nivolumab combination by itself. Deep response rate means the CR rate plus the PR rate, counting only those PRs that reached more than 50% tumor volume reduction. Keep in mind that the standard threshold for PRs is 30% tumor reduction. Enrollment continues, and we're aiming for a possible presentation of the most recent data from this trial at a meeting during the fourth quarter. Beyond RCC, we also anticipate new preclinical data that will underscore cifo's potential for treating prostate cancer. These preclinical and early clinical findings will be shared at SITC in November. The presentation, coming from investigators at UCSF, will focus on mechanism and potential biomarkers relevant to prostate cancer. When it comes to our anti-CD73 antibody, mupadolimab, our partner Angel Pharmaceutical is still enrolling patients in a Phase I/Ib clinical trial in China, testing mupadolimab both as a monotherapy and in combination with pembrolizumab in patients who have non-small cell lung cancer. Given the partial responses observed with monotherapy, an expansion cohort study looking at monotherapy in relapsed non-small cell lung cancer is now underway in China. To wrap up what lies ahead for the rest of 2024: there are key clinical milestones for soquelitinib that we believe will boost recognition of the distinct mechanism of action involving ITK inhibition and its capacity to target a broad spectrum of indications. The milestones coming up are as follows: Regarding soquelitinib, first, launching our registrational Phase III clinical trial of soquelitinib in PTCL during September; second, sharing interim results from our soquelitinib Phase I atopic dermatitis trial in the fourth quarter, and then final data in early 2025; third, presenting preclinical data in other immune diseases — additional immune disease indications at the ACR meeting in November; fourth, kicking off a Phase II clinical trial with soquelitinib in solid tumors in the fourth quarter, with initial data expected in the second half of 2025. As for ciforadenant, reporting further data from the cifo Phase Ib/II trial in frontline renal cell cancer in the fourth quarter and reporting data in prostate cancer at the SITC meeting in November. Our present cash runway — our present cash provides runway into late 2025, enabling us to carry out these important milestones and further show the value of our programs, and especially, the major opportunity for ITK inhibition in immunology and in cancer. We anticipate giving updates on our programs over the upcoming quarters. I will now hand the call over to the operator for a Q&A period.
Li Watsek
analystNice work on the advances. Perhaps just one question regarding the Phase I results in atopic dermatitis coming in Q4, Rich — could you help shape what we ought to anticipate, and what the hurdle would be when it comes to EASI score? And given that you're likely testing several doses, how should we view dose response in autoimmune?
Richard Miller
executiveLi, thanks for asking those. By the fourth quarter, my expectation is that we can share safety and efficacy findings from the initial 2 cohorts of our trial. Those initial 2 cohorts are currently enrolling patients dosed at 100 milligrams BID, followed by 200 milligrams once-a-day, since our aim is to get to once-a-day administration. As for where we'd draw the line for success, I'd put it this way: most patients showing EASI scores improved by more than 50%. Keep in mind this treatment runs 28 days, so that's a fairly strong result over a brief window. My expectation is that those results will be similar to what appeared in early clinical studies of DUPIXENT and other rival products. So being competitive is our aim. Over the longer term, we believe we hold an edge thanks to an oral drug, a very favorable safety profile, and a novel mechanism that should apply across a variety of immune and inflammatory conditions.
Li Watsek
analystAll right, excellent. That brings me to another item. Rich, you mentioned moving into additional immune conditions. Regarding the amount you plan to administer, would you anticipate that staying identical or varying somewhat depending on which condition it is?
Richard Miller
executiveMy expectation is that it stays identical. I don't anticipate observing major variations when it comes to dosing. Keep in mind, we possess an extremely accurate method for assessing the pharmacodynamic impact of our medication; we are able, in fact, to quantify what fraction of the target's active site our drug occupies; plus we are starting to gain insight through additional biological functional tests, for instance the generation of various cytokines. Therefore, my expectation is there won't be inconsistency across different diseases.
Roger Song
analystLet's start with the Phase I atopic dermatitis study and its enrollment. What sort of baseline should we anticipate for these patients? Since you're permitting them to have received at least one prior therapy, should we figure that the majority will come in having already tried biologics, or will they have gone through several prior lines? Also, since you've given us some expectation around EASI 50 for most of the patients, how ought we to think about comparability with other AD trials?
Richard Miller
executiveWell, up to now, we've observed certain patients who've been on biologics and certain ones who haven't. So I don't — I can't really say I'm in a position to forecast what we'll end up with. But how this disease gets treated has been shifting across the years, since other therapies that work are available. And so I'm not certain, Roger, that I can forecast precisely what combination we'll see in that Phase I trial. My expectation would be that we'll see a little bit of everything.
Roger Song
analystYes, that's clear. We'll dig into that a bit more — right, at the point when you share the data. Then, regarding solid tumors, could you walk us through the reasoning behind selecting RCC as the initial solid tumor indication? And is there any preclinical work that might back up that thinking?
Richard Miller
executiveAlright, fair question. To start, keep in mind that soquelitinib, or selective ITK inhibition, produces something known as Th1 skewing. That was anticipated from genetic knockout research conducted 20 years back, and it drove our decision to create a highly selective agent that suppresses Th2 and Th17 while bringing about what are termed Th1 helper T-cells. Those in turn boost the generation of CD8 killer cells. In animal models, we've demonstrated — and other researchers have demonstrated this too — that we trigger a host antitumor response not only toward T-cell lymphomas but, in mice, we've observed activity against renal cell cancer, GI tumors, lung tumors, melanoma, and B-cell lymphoma. Additional solid tumors have been observed by other investigators. Now, the rationale for choosing renal cell cancer for the clinical trial is, first, renal cell cancer is what's known as an immune responsive disease. We didn't want to pursue — we preferred to target a disease where we understood the immune system played a key role in keeping the tumor in check. We also possessed mouse data demonstrating that soquelitinib performed very effectively in tumors resistant to anti-PD-1 therapy. So renal cell cancer gave us an excellent chance to treat — to treat patients who had already failed an anti-PD-1 or a checkpoint inhibitor and whose tumors were immunoresponsive. And lastly, we have an excellent relationship with the Kidney Cancer Research Consortium. We've truly enjoyed collaborating with these people. They are the foremost global authorities on renal cell cancer. So this gave us a truly unique chance to move rapidly into renal cell cancer. And one more thing — I should mention that if you look at the last ASCO meeting, even though ipi and nivo are unquestionably producing more PRs and CRs and PFS has gotten better, and so on. When you examine some of the original data comparing treatment checkpoint inhibitor therapy with SUTENT, the standard of care, it isn't clear that survival has gotten better. So there's obviously a need for renal cell therapies with a different mechanism of action that might extend that PFS even further and lead to better survival. So renal is a good disease; but it's a good question. You could also make the case for studying melanoma, studying lung cancer — there's gastric cancer, there are lots of other immune-responsive tumors. But we were well positioned to do renal, and our rationale for that was very strong.
Roger Song
analystGot it — several variables shape which indication gets picked. Perhaps one final, brief item: since you're broadening the use case for soquelitinib, how are we to interpret the strategic call about doing all of this on your own? Or could it be that at some stage you'll seek a partnership with another firm so the program can be scaled up more efficiently?
Richard Miller
executiveHonestly, the data has us very enthusiastic — from lymphoma as well as our initial findings in immune disease, and let's not forget the compelling preclinical results. Our aim is to advance soquelitinib in immune diseases alongside cancer at maximum speed. Naturally, numerous partnership conversations are underway. Mr. Arcara, who serves as our Chief Business Officer, is hard at work on them. Even so, we're driving both efforts ahead as swiftly as possible. Once we engage with potential partners, we'll figure out — weighing the economics, the data, and so forth — the right way to grow these programs.
Aydin Huseynov
analystNice work on the quarter's advances. Also, well done on turning 1 PR into a CR — that leaves you with 6 CRs and 3 PRs, whereas typically it's the reverse, with most patients in other studies achieving PR. So, how would you characterize these CR patients? What do you think — why are they doing so well compared with those who had PRs — CRs, complete responses?
Richard Miller
executiveLet me start with how I'd characterize the patient. If you consider our most recent CR, that individual progressed through CHOEP. CHOEP is a harsh chemotherapy regimen. He progressed despite it. It didn't work for him. After that, he received a regimen known as ICE — ifosfamide, cisplatin and etoposide. Extremely aggressive chemotherapy. That patient achieved only a brief partial response before relapsing, and then upon receiving our drug, achieved a CR; that's my characterization. Now, why does this occur? I can't really provide a definitive answer, except to say that the mechanism here is entirely distinct. Our drug works through a completely different mechanism of action. And despite this patient having chemorefractory disease, the immune-based strategy proved highly effective for him; so as of now, we lack, I'd say, a particular biomarker for predicting who will respond. That said, in our Phase III trial, which will enroll more patients, we are collecting biopsies; we also have a research initiative that will employ a range of highly advanced methods, examining tumor sequencing, sequencing of the host infiltrate within these tumors, and naturally their circulating normal blood cells, in an effort to determine what's predictive. I should mention too that nearly every patient in our study is what's called GATA3-positive. GATA3 is a transcription factor referred to as the master regulator of helper T-cells, or Th2 cells. Tumors that are GATA3-positive are recognized, according to the literature, as carrying a very poor prognosis. Very poor; indeed, my colleague Ryan Wilcox at the University of Michigan published a paper some years back in PTCL showing that GATA3-positive patients who entered hospice did — just as well as those who received chemotherapy. So this is a truly awful disease, and I believe we're achieving a very meaningful impact on — essentially a patient population that's impossible to manage.
Aydin Huseynov
analystThat's really useful. I also wanted to ask about ITK inhibitors from the second generation. Could you remind everyone how soquelitinib is going to be different? And what's your sense of when they'll reach the clinic?
Richard Miller
executiveRegarding the ITK inhibitors in the second and third generations — certain ones have chemical structures that resemble each other, with only minor modifications. Others have chemical structures that are quite distinct. A few are covalent, while a few are non-covalent, or reversible. We have been looking at every one of those agents across the different biologic assays we run, and we observe certain differences in how they affect things like Th2 compared with Th17 compared with Th1. So I'd say right now we remain in the middle of figuring out which next generation to take into IND-enabling studies. My estimate is that we are 12 to 15 months out from studies in immune or inflammatory diseases. Meanwhile, we push ahead aggressively with soquelitinib in immunology, immune diseases, and cancer.
Aydin Huseynov
analystNice work on the advances made during this quarter.
Jeff Jones
analystNice work on everything moving forward. It's wonderful to see. So I suppose one brief thing regarding the AD data. Do you have any idea how this will be shown? Would that happen at a conference? Or might you handle it in a less formal way, through a press release or an investor call?
Richard Miller
executiveJeff, most likely through an investor call of some kind, or an R&D update, or along those lines. I don't think there's a meeting near the close of the year that fits. We do have meetings, though they aren't really focused on immune diseases; we'll be at SITC, we'll be at a GU oncology meeting in November; but most likely it will take the shape of a press release or investor conference call, or something similar.
Jeff Jones
analystExcellent. Regarding that pivotal study, it sounds as though you're just about to get it started. Are there any gating items we ought to be considering that must be cleared before you can proceed? Or is it all set, and I believe you mentioned September?
Richard Miller
executiveThere are no gating items; FDA has given us full clearance. We've been in close contact with them. Our sites are prepared. I think contracts are even signed with a few of them, along with all the necessary approvals. At this point, we're only stress-testing certain computer systems of ours to confirm there aren't any glitches. Honestly, as far as I can tell, nothing stands in our way at present.
Jeff Jones
analystThen for my final question, I was hoping for a bit more clarity regarding the next generation of ITK inhibitors that came up earlier; my understanding is they're roughly more than 12 months from reaching the clinic, if I heard that right. But perhaps you could shed some light there; and would you consider advancing these into the clinic on your own? Or does that depend on securing a partner for some of those I&I indications, as you've mentioned previously?
Richard Miller
executiveWe are looking at both possibilities. Regarding our backup in the second and third-generation compounds, the first thing is that additional animal testing is required. We believe particular ones might work better for specific diseases; so we simply need to gather more data on that; but as of now, soquelitinib is something we're very enthusiastic about for immune diseases.
Graig Suvannavejh
analystGood to see the headway being made. If I may, the first thing I'd like to ask about is the present budget or operating plan alongside the cash runway. Could you remind us what the existing budget truly permits regarding which programs receive funding? And again, taking into account how cash stands right now, up to what point are those programs financed?
Leiv Lea
executiveCertainly. Regarding the programs we've outlined — whether that means launching the Phase III study or wrapping up our Phase I/Ib study, the solid tumor study and the cifo study — every one of them sits within the budget, together with our cash projection through the close of 2025.
Graig Suvannavejh
analystTurning to that pivotal Phase III trial you plan to kick off by September — I may have missed it earlier, but could you give us a rough picture of the expected timing for reaching a data readout on that one?
Richard Miller
executiveLet me clarify one thing first: for the Phase III registration study, my statement was that it begins in September, not by September. Enrollment in that trial totals 150 patients. An interim look happens at 65 events, which are PFS events; that likely comes about 12 months after the trial gets underway. Enrollment will take 18 months to finish, and the data — under 2 years to have it, meaning top line data.
Richard Miller
executiveAll right. Thanks to our operator. And thanks to all of you for joining this call. We're eager to bring you updates on upcoming conference calls. Thanks so much.
Operator
operatorI appreciate it. That brings today's call to a close. Thanks to everyone for joining in. You're free to drop off now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.